Levosimendan Bioglan

Levosimendan, the active ingredient in Levosimendan Bioglan, is a calcium sensitizer / inodilator presented as a solution for injection for intravenous use. It treats acute decompensated heart failure in adult patients.

GNH USA supplies Levosimendan Bioglan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Levosimendan is indicated for the management of acute decompensated heart failure, a condition characterized by sudden worsening of cardiac function.

Acute decompensated heart failure: improves cardiac output and reduces symptoms of congestion. Severe left ventricular dysfunction: enhances myocardial contractility to support circulation. Post‑cardiac surgery low‑output syndrome: provides hemodynamic support during recovery.

Levosimendan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypotension: drop in blood pressure, especially during infusion. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Severe hypotension: may require intervention. - Myocardial ischemia: chest pain or ECG changes indicating reduced blood flow. - Anaphylactic reactions: rare allergic responses requiring emergency treatment.

Use Levosimendan with careful clinical monitoring and consideration of patient‑specific factors.

Cardiovascular monitoring: observe blood pressure and heart rate continuously during infusion. Renal impairment: adjust therapy or monitor closely in patients with reduced kidney function. Hepatic impairment: use with caution in patients with liver disease. Concomitant vasodilators: may potentiate hypotensive effects; dose adjustments may be needed. Pregnancy: safety not established; avoid unless benefits outweigh risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with several medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Sodium nitroprusside: additive hypotensive effect. - Other inotropes (e.g., dobutamine): risk of excessive cardiac stimulation. - Phosphodiesterase inhibitors (e.g., milrinone): may increase arrhythmia risk.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt the inotropic response. - Calcium channel blockers: can affect hemodynamic stability. - ACE inhibitors or ARBs: monitor blood pressure for additive hypotension.